GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANG-PD · Mar 31, 2019

American National Group Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001039828-19-000026Insurance
Cash60thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.cash

$1.1B · CORE · VALID

Policy-benefit growth10thOwn-history percentile · N=20
Evidence method

Yoy · gp.insurance.policy_benefits

-23.11% · OPTIONAL · VALID

Net-income growth11thOwn-history percentile · N=18
Evidence method

Yoy · gp.fundamentals.net_income

-121.29% · CORE · VALID

Premium growth0thOwn-history percentile · N=20
Evidence method

Yoy · gp.insurance.premiums

-40.24% · CORE · VALID

Revenue growth100thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

741.85% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History51 statesSelf-history eligible
Period transition

What moved in the state?

Cash Increased
Previous
$344.4M
Current
$1.1B
Delta
$771.5M
Claims Growth Decreased
Previous
-8.54%
Current
-23.11%
Delta
-14.57%
Earnings Growth Decreased
Previous
162.26%
Current
-121.29%
Delta
-283.54%
Premium Growth Decreased
Previous
-22.64%
Current
-40.24%
Delta
-17.60%
Revenue Growth Increased
Previous
-60.25%
Current
741.85%
Delta
802.09%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.